Pharmacokinetic-Pharmacodynamic modeling of the analgesic effect of bupredermTM, in mice

Min-Hyuk Yun, Seung-Wei Jeong, Chaul-Min Pai, Sun-Ok Kim

.

DOI: 10.4236/health.2010.28124                

Abstract

Purpose: BupredermTM－Buprenorphine transdermal delivery system (BTDS) was developed for the treatment of post-operative and chronic pains. This study examined the relationship between the plasma concentration of buprenorphine and its analgesic effect (tail flick test) in order to assess the usefulness of pharmacokinetic-pharmacodynamic (PK-PD) modeling in describing this relationship. Methods: After patch application, plasma concentrations of bu- prenorphine in mice were measured for 72 hours with a validated LC/MS/MS system, and the analgesic effects were assessed by tail flick test for the period of 24 hours. A modified two- compartment open model was used to explain the PK properties of BTDS, and the PD model was characterized by slow receptor binding. Results: The peak buprenorphine level in plasma was achieved at 1-24 h and the effective therapeutic drug concentration was maintained for 72 hours. BupredermTM induced prolongation of tail-flick latency in a dose and time dependent manner. Maximum analgesic effect was attained at 3-6 h and was maintained for 24 h after patch application. Counter-clockwise hysteresis between the plasma concentration and the analgesic efficacy of BTDS was observed after BupredermTM application, indicating there was a delay between plasma concentrations and the effect observed. From the developed PK-PD model, Kd values (0.69-0.82 nM) that were derived from the pharmacodynamic parameters (Kon and Koff) are similar to the reported values (Kd = 0.76 ± 0.14 nM). Good agreement between the predicted and observed values was noted for the rate of change in analgesic effect data (R2 = 0.822, 0.852 and 0.774 for 0.24, 0.8 and 2.4 mg/patch, respectively). Conclusions: The established PK- PD model successfully described the relationship between plasma concentration of buprenorphine and its analgesic efficacy measured by the tail flick test. Our model might be useful in estimation and prediction of onset, magnitude and time course of concentration and pharmacological effects of BTDS and will be useful to simulate PK-PD profiles with clinical regimens.

Keywords

Pharmacokinetic-Pharmacodynamic Modeling; BupredermTM; Buprenorphine; Transdermal System; Slow Receptor-Binding Model

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Jasinski, D.R., Pevnick, J.S. and Griffith, J.D. (1978) Human pharmacology and abuse potential of the analgesic buprenorphine. Archives of General Psychiatry, 35(4), 501-516.
[2]	Lewis, J.W. (1985) Buprenorphine. Drug and Alcohol Dependence, 14(3-4), 363-372.
[3]	Hambrook, J.M. and Rance, M.J. (1976) The interaction of buprenorphine with opiate receptor. In: Kosterlitz, H.W., Ed., Opiates and Endogenous Opioid Peptides, Elsevier/North Holland Biomedical Press, Amsterdam, 295-301.
[4]	Adrianensen, H., Mattlaer, B. and Vanmeenen, H. (1985) A longtermopen, clinical and pharmacokinetic assessment of sublingual buprenorphine in patients suffering from chronic pain. Acta Anaesthesiologica, 36(1), 33-40.
[5]	Amass, L., Bickel, W.K., Higgins, S.T. and Badger, G.J. (1994) Alternate-day dosing during buprenorphine treatment of opoid dependence. Life Science, 54(17), 1215- 1228.
[6]	Strain, E.C., Stitzer, M.L., Liebson, L.A. and Bigelow, G.E. (1994) Comparison of buprenorphine and methadone in the treatment of opiod dependence. American Journal of Psychiatry, 151(7), 1025-1030.
[7]	Downing, J.W., Leary, W.P. and White, E.S. (1977) Buprenorphine: A new potent long-acting synthetic analgesic. Comparison with morphine. British Journal of Anaesthesia, 49(3), 251-255.
[8]	Bullingham, R.E.S., McQuay, H.J., Moore, A. and Bennett, M.D.R. (1980) Buprenorphine kinetics. Clinical Pharmacology & Therapeutics, 28(5), 667-672.
[9]	Walsh, S.L, Preston, K.L., Stitzer, M.L., Cone, E.J. and Bigelow, G.E. (1994) Clinical Pharmacology of buprenorphine: Ceiling effects at high doses, Clinical Pharmacology & Therapeutics, 55(5), 569-580.
[10]	Evans, H.C. (2003) Transdermal buprenorphine. Drugs, 63(19), 1999-2010.
[11]	Park, I., Kim, D.W., Song, J.D., In, C.H., Jeong, S.W., Lee, S.H., Min, B.C., Lee D.H. and Kim, S.O. (2008) BupredermTM, a new transdermal delivery system of buprenorphine: Pharmacokinetic, efficacy and skin irritancy studies. Pharmaceutical Research, in press.
[12]	Perez-Urizar, J., Granados-Soto, V. and Flores-Murrieta, F.J. (2000) Pharmacokinetic-pharmacodynamic modeling: Why? Archives of Medical Research, 31(6), 539-545.
[13]	Van der Graaf, P.H. and Danhof, M. (1997) Analysis of frug-receptor interactions in vivo: A new approach in pharmacokinetic-parmacodynamic modeling. International Journal of Clinical Pharmacology, Therapy & Toxicology, 35, 442-446.
[14]	Gopal, S., Tzeng, T-B. and Cowan, A. (2002) Characterization of the pharmacokinetics of buprenorphine and norbuprenorphine in rats after intravenous bolus administration of buprenorphine. European Journal of Pharmaceutical Sciences, 15(3), 287-293.
[15]	Kogel, B., Christoph, T., Straβburger, W. and Friderichs, E. (2005) Interation of μ-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice. European Journal of Pain, 9(5), 599-611.
[16]	Ohtani, M., Kotaki, H., Sawada, Y. and Iga, T. (1995) Comparative analysis of buprenorphine- & norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling. Journal of Pharmacology and Experimental Therapeutics, 272(2), 505- 510.
[17]	Yassen, A., Olofsen, E., Dahan, A. and Danhof, M. (2005) Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics. Journal of Pharmacology and Experimental Therapeutics, 313(3), 1136-1149.
[18]	Hernandez-Delgadillo, G.P. and Cruz, S.L. (2006) Endogenous opioids are involved in morphine and dipyrone analgesic potentiation in the tail flick test in rats. European Journal of Pharmacology, 546(1-3), 54-59.
[19]	Shimada, S., Nakazima, Y., Yamamoto, K., Sawada, Y. and Iga, T. (1996) Comparative pharmacodynamics of eight calcium channel blocking agents in Japanese essential hypertensive patients. Biological & Pharmaceutical Bulletin, 19(3), 430-437.
[20]	Eaton1, M. (2003) Common animal models for spasticity and pain. Journal of Rehabilitation Research and Development, 40(4), 41-54.
[21]	Grumbach, L. (1996) The prediction of analgesic activity in man by animal testing. In: Knighton, R.S. and Dumke, P.R., Eds., 15th International Symposium, Detroit, 1964. Little Brown, Boston, 163-182.
[22]	Lutfy, K., Eitan, S., Bryant, CD., Yang, YC., Saliminejad, N. and Walwyn, W. (2003) Buprenorphine-induced antinociception is mediated by muopioid receptors and compromised by concomitant activation of opioid receptor- like receptors. Journal of Neuroscience, 23(32), 10331- 10337.
[23]	Villiger, J.W. and Taylor, K.M. (1981) Buprenorphine: characteristics of binding sites in the rat central nervous system. Life Science, 29(26), 2699-2708.
[24]	Cowan, A. (1995) Updaate on the general pharmacology of buprenorphin. In: Cowan, A. and Lewis J.W., Eds., Buprenorphine: Combating Drug Abuse with a Unique Opioid, Wiley-Liss, New York, 31-47.